Similarly, PRRT was a more common choice of therapy in slower proliferating neoplasias: for Ki67 proliferation indices of up to 20%, the fraction of cases treated with PRRT was 74% (50/68), while these numbers dropped to 50% (5/10) for proliferation indices of up to 50%, and only 1 (7%) of 14 cases with Ki67 above 50% received PRRT. The gene discussed is MKI67; the disease is neoplasm.